Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

Molecular Therapy

Volumn 25, Issue 2, 2017, Pages 547-559

  Bliss, Carly M ^a   Drammeh, Abdoulie ^b   Bowyer, Georgina ^a   Sanou, Guillaume S ^c   Jagne, Ya Jankey ^b   Ouedraogo, Oumarou ^c   Edwards, Nick J ^a   Tarama, Casimir ^c   Ouedraogo, Nicolas ^c   Ouedraogo, Mireille ^c   Njie Jobe, Jainaba ^b   Diarra, Amidou ^c   Afolabi, Muhammed O ^b   Tiono, Alfred B ^c   Yaro, Jean Baptiste ^c   Adetifa, Uche J ^b   Hodgson, Susanne H ^d   Anagnostou, Nicholas A ^d   Roberts, Rachel ^d   Duncan, Christopher J A ^d   Cortese, Riccardo ^e   Viebig, Nicola K ^f   Leroy, Odile ^f   Lawrie, Alison M ^d   Flanagan, Katie L ^b   Kampmann, Beate ^b,g   Imoukhuede, Egeruan B ^d   Sirima, Sodiomon B ^c   Bojang, Kalifa ^b   Hill, Adrian V S ^a,d   Nébié, Issa ^c   Ewer, Katie J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Medical Research Council Unit   (Gambia)

^c Burkina Faso   (Burkina Faso)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e Universitäts Klinikum Heidelberg ^*  (Switzerland)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antibodies; malaria; Phase I trial; T cells; vaccine; viral vectors

Indexed keywords

MALARIA VACCINE; VIRUS VECTOR; IMMUNOGLOBULIN CLASS; PROTOZOON ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALARIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINE IMMUNOGENICITY; VACCINIA VIRUS; WEST AFRICAN; ADVERSE EFFECTS; AFRICA; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE VECTOR; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; MALARIA, FALCIPARUM; METABOLISM; NEWBORN; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; VACCINATION;

AFRICA, WESTERN; ANTIBODIES, PROTOZOAN; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN ISOTYPES; INFANT; INFANT, NEWBORN; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES; VACCINATION;

EID: 85016326575     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.11.003     Document Type: Article

References (53)

1. 1 WHO-UNICEF (2014). Global immunization data. http://www.who.int/immunization/monitoring_surveillance/global_immunization_data.pdf.
2. + T cells. Vaccine 33 (2015), 85–91.
3. 3 Plotkin, S.A., Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17 (2010), 1055–1065.
4. 4 Koff, W.C., Burton, D.R., Johnson, P.R., Walker, B.D., King, C.R., Nabel, G.J., Ahmed, R., Bhan, M.K., Plotkin, S.A., Accelerating next-generation vaccine development for global disease prevention. Science, 340, 2013, 1232910.
5. 5 Welsh, R.M., Assessing CD8 T cell number and dysfunction in the presence of antigen. J. Exp. Med. 193 (2001), F19–F22.
6. 6 Martinez, X., Regner, M., Kovarik, J., Zarei, S., Hauser, C., Lambert, P.H., Leclerc, C., Siegrist, C.A., CD4-independent protective cytotoxic T cells induced in early life by a non-replicative delivery system based on virus-like particles. Virology 305 (2003), 428–435.
7. 7 Adkins, B., Leclerc, C., Marshall-Clarke, S., Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4 (2004), 553–564.
8. 8 PrabhuDas, M., Adkins, B., Gans, H., King, C., Levy, O., Ramilo, O., Siegrist, C.A., Challenges in infant immunity: implications for responses to infection and vaccines. Nat. Immunol. 12 (2011), 189–194.
9. 9 Siegrist, C.A., Neonatal and early life vaccinology. Vaccine 19 (2001), 3331–3346.
10. 10 Vekemans, J., Ota, M.O., Wang, E.C., Kidd, M., Borysiewicz, L.K., Whittle, H., McAdam, K.P., Morgan, G., Marchant, A., T cell responses to vaccines in infants: defective IFNgamma production after oral polio vaccination. Clin. Exp. Immunol. 127 (2002), 495–498.
11. 11 Rowe, J., Macaubas, C., Monger, T.M., Holt, B.J., Harvey, J., Poolman, J.T., Sly, P.D., Holt, P.G., Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. Infect. Immun. 68 (2000), 3873–3877.
12. 12 WHO. World Malaria Report 2013. 2013, World Health Organisation, Geneva.
13. 13 Bojang, K.A., Milligan, P.J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K.E., Ballou, W.R., Conway, D.J., Reece, W.H., Gothard, P., et al., RTS, S Malaria Vaccine Trial Team. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001), 1927–1934.
14. 14 Kester, K.E., McKinney, D.A., Tornieporth, N., Ockenhouse, C.F., Heppner, D.G., Hall, T., Krzych, U., Delchambre, M., Voss, G., Dowler, M.G., et al., RTS,S Malaria Vaccine Evaluation Group. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183 (2001), 640–647.
15. 15 Agnandji, S.T., Lell, B., Fernandes, J.F., Abossolo, B.P., Methogo, B.G., Kabwende, A.L., Adegnika, A.A., Mordmüller, B., Issifou, S., Kremsner, P.G., et al., RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367 (2012), 2284–2295.
16. 16 RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386 (2015), 31–45.
17. 17 Moorthy, V.S., Newman, R.D., Okwo-Bele, J.M., Malaria vaccine technology roadmap. Lancet 382 (2013), 1700–1701.
18. 18 Malaria Vaccine Funders Group (2013). Malaria vaccine technology roadmap. http://www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1.
19. 19 Yoshida, N., Potocnjak, P., Nussenzweig, V., Nussenzweig, R.S., Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J. Exp. Med. 154 (1981), 1225–1236.
20. 20 Ndungu, F.M., Mwacharo, J., Kimani, D., Kai, O., Moris, P., Jongert, E., Vekemans, J., Olotu, A., Bejon, P., A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS ONE, 7, 2012, e52870.
21. + T cell responses and protection against Plasmodium falciparum infection. PLoS ONE, 8, 2013, e61395.
22. 22 Lumsden, J.M., Schwenk, R.J., Rein, L.E., Moris, P., Janssens, M., Ofori-Anyinam, O., Cohen, J., Kester, K.E., Heppner, D.G., Krzych, U., Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS ONE, 6, 2011, e20775.
23. 23 Agnandji, S.T., Lell, B., Soulanoudjingar, S.S., Fernandes, J.F., Abossolo, B.P., Conzelmann, C., Methogo, B.G., Doucka, Y., Flamen, A., Mordmüller, B., et al., RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365 (2011), 1863–1875.
24. 24 Chattopadhyay, R., de la Vega, P., Paik, S.H., Murata, Y., Ferguson, E.W., Richie, T.L., Ooi, G.T., Early transcriptional responses of HepG2-A16 liver cells to infection by Plasmodium falciparum sporozoites. J. Biol. Chem. 286 (2011), 26396–26405.
25. 25 Cheng, Q., Lawrence, G., Reed, C., Stowers, A., Ranford-Cartwright, L., Creasey, A., Carter, R., Saul, A., Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am. J. Trop. Med. Hyg. 57 (1997), 495–500.
26. 26 Rickman, L.S., Jones, T.R., Long, G.W., Paparello, S., Schneider, I., Paul, C.F., Beaudoin, R.L., Hoffman, S.L., Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am. J. Trop. Med. Hyg. 43 (1990), 441–445.
27. 27 Murphy, J.R., Baqar, S., Davis, J.R., Herrington, D.A., Clyde, D.F., Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. J. Clin. Microbiol. 27 (1989), 1434–1437.
28. 28 Hill, A.V., Reyes-Sandoval, A., O'Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A., Folgori, A., Colloca, S., Cortese, R., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6 (2010), 78–83.
29. 29 McConkey, S.J., Reece, W.H., Moorthy, V.S., Webster, D., Dunachie, S., Butcher, G., Vuola, J.M., Blanchard, T.J., Gothard, P., Watkins, K., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003), 729–735.
30. 30 O'Hara, G.A., Duncan, C.J., Ewer, K.J., Collins, K.A., Elias, S.C., Halstead, F.D., Goodman, A.L., Edwards, N.J., Reyes-Sandoval, A., Bird, P., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205 (2012), 772–781.
31. 31 Ogwang, C., Afolabi, M., Kimani, D., Jagne, Y.J., Sheehy, S.H., Bliss, C.M., Duncan, C.J., Collins, K.A., Garcia Knight, M.A., Kimani, E., et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE, 8, 2013, e57726.
32. 32 Kimani, D., Jagne, Y.J., Cox, M., Kimani, E., Bliss, C.M., Gitau, E., Ogwang, C., Afolabi, M.O., Bowyer, G., Collins, K.A., et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol. Ther. 22 (2014), 1992–2003.
33. 33 Hodgson, S.H., Ewer, K.J., Bliss, C.M., Edwards, N.J., Rampling, T., Anagnostou, N.A., de Barra, E., Havelock, T., Bowyer, G., Poulton, I.D., et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J. Infect. Dis. 211 (2015), 1076–1086.
34. 34 Ewer, K.J., O'Hara, G.A., Duncan, C.J., Collins, K.A., Sheehy, S.H., Reyes-Sandoval, A., Goodman, A.L., Edwards, N.J., Elias, S.C., Halstead, F.D., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun., 4, 2013, 2836.
35. 35 Ogwang, C., Kimani, D., Edwards, N.J., Roberts, R., Mwacharo, J., Bowyer, G., Bliss, C., Hodgson, S.H., Njuguna, P., Viebig, N.K., et al., MVVC Group. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci. Transl. Med., 7, 2015, 286re5.
36. 36 Shearer, W.T., Rosenblatt, H.M., Gelman, R.S., Oyomopito, R., Plaeger, S., Stiehm, E.R., Wara, D.W., Douglas, S.D., Luzuriaga, K., McFarland, E.J., et al., Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J. Allergy Clin. Immunol. 112 (2003), 973–980.
37. 37 Ceesay, S.J., Casals-Pascual, C., Erskine, J., Anya, S.E., Duah, N.O., Fulford, A.J., Sesay, S.S., Abubakar, I., Dunyo, S., Sey, O., et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372 (2008), 1545–1554.
38. 38 Tiono, A.B., Kangoye, D.T., Rehman, A.M., Kargougou, D.G., Kaboré, Y., Diarra, A., Ouedraogo, E., Nébié, I., Ouédraogo, A., Okech, B., et al. Malaria incidence in children in South-West Burkina Faso: comparison of active and passive case detection methods. PLoS ONE, 9, 2014, e86936.
39. 39 Ouédraogo, A., Tiono, A.B., Diarra, A., Sanon, S., Yaro, J.B., Ouedraogo, E., Bougouma, E.C., Soulama, I., Gansané, A., Ouedraogo, A., et al. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso. PLoS ONE, 8, 2013, e50036.
40. 40 Afolabi, M.O., Tiono, A.B., Adetifa, U.J., Yaro, J.B., Drammeh, A., Nébié, I., Bliss, C., Hodgson, S.H., Anagnostou, N.A., Sanou, G.S., et al. Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol. Ther. 24 (2016), 1470–1477.
41. 41 Ceesay, S.J., Casals-Pascual, C., Nwakanma, D.C., Walther, M., Gomez-Escobar, N., Fulford, A.J., Takem, E.N., Nogaro, S., Bojang, K.A., Corrah, T., et al. Continued decline of malaria in The Gambia with implications for elimination. PLoS ONE, 5, 2010, e12242.
42. 42 Ho, M., Webster, H.K., Looareesuwan, S., Supanaranond, W., Phillips, R.E., Chanthavanich, P., Warrell, D.A., Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J. Infect. Dis. 153 (1986), 763–771.
43. 43 Millington, O.R., Gibson, V.B., Rush, C.M., Zinselmeyer, B.H., Phillips, R.S., Garside, P., Brewer, J.M., Malaria impairs T cell clustering and immune priming despite normal signal 1 from dendritic cells. PLoS Pathog. 3 (2007), 1380–1387.
44. 44 White, M.T., Verity, R., Griffin, J.T., Asante, K.P., Owusu-Agyei, S., Greenwood, B., Drakeley, C., Gesase, S., Lusingu, J., Ansong, D., et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15 (2015), 1450–1458.
45. 45 Ajua, A., Lell, B., Agnandji, S.T., Asante, K.P., Owusu-Agyei, S., Mwangoka, G., Mpina, M., Salim, N., Tanner, M., Abdulla, S., et al. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants. Malar. J., 14, 2015, 72.
46. 46 Gans, H., Yasukawa, L., Rinki, M., DeHovitz, R., Forghani, B., Beeler, J., Audet, S., Maldonado, Y., Arvin, A.M., Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J. Infect. Dis. 184 (2001), 817–826.
47. 47 Siegrist, C.A., Aspinall, R., B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9 (2009), 185–194.
48. 48 Halsey, N., Galazka, A., The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull. World Health Organ. 63 (1985), 1151–1169.
49. 49 Gans, H.A., Arvin, A.M., Galinus, J., Logan, L., DeHovitz, R., Maldonado, Y., Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 280 (1998), 527–532.
50. 50 Marchant, A., Appay, V., Van Der Sande, M., Dulphy, N., Liesnard, C., Kidd, M., Kaye, S., Ojuola, O., Gillespie, G.M., Vargas Cuero, A.L., et al. Mature CD8(+) T lymphocyte response to viral infection during fetal life. J. Clin. Invest. 111 (2003), 1747–1755.
51. 51 Hermann, E., Truyens, C., Alonso-Vega, C., Even, J., Rodriguez, P., Berthe, A., Gonzalez-Merino, E., Torrico, F., Carlier, Y., Human fetuses are able to mount an adultlike CD8 T-cell response. Blood 100 (2002), 2153–2158.
52. 52 Green, C.A., Scarselli, E., Sande, C.J., Thompson, A.J., de Lara, C.M., Taylor, K.S., Haworth, K., Del Sorbo, M., Angus, B., Siani, L., et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci. Transl. Med., 7, 2015, 300ra126.
53. 53 Biswas, S., Choudhary, P., Elias, S.C., Miura, K., Milne, K.H., de Cassan, S.C., Collins, K.A., Halstead, F.D., Bliss, C.M., Ewer, K.J., et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS ONE, 9, 2014, e107903.